In today’s session TESARO Inc (TSRO) recorded an unusually high (994) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the November, 2016 put, expecting serious TSRO decrease. With 994 contracts traded and 1304 open interest for the Nov, 16 contract, it seems this is a quite bearish bet. The option with symbol: TSRO161118P00110000 closed last at: $8.3 or 29.7% up. About 58,304 shares traded hands. TESARO Inc (NASDAQ:TSRO) has risen 170.16% since March 16, 2016 and is uptrending. It has outperformed by 164.62% the S&P500.
Analysts await TESARO Inc (NASDAQ:TSRO) to report earnings on November, 3. They expect $-1.92 EPS, down 15.66% or $0.26 from last year’s $-1.66 per share. After $-1.28 actual EPS reported by TESARO Inc for the previous quarter, Wall Street now forecasts 50.00% negative EPS growth.
TESARO Inc (NASDAQ:TSRO) Ratings Coverage
Out of 12 analysts covering Tesaro Inc (NASDAQ:TSRO), 11 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 92% are positive. $139 is the highest target while $56 is the lowest. The $97.33 average target is -12.52% below today’s ($111.26) stock price. Tesaro Inc has been the topic of 20 analyst reports since August 24, 2015 according to StockzIntelligence Inc. The stock of TESARO Inc (NASDAQ:TSRO) has “Sell” rating given on Tuesday, September 1 by Zacks. As per Friday, August 12, the company rating was initiated by RBC Capital Markets. Leerink Swann initiated it with “Outperform” rating and $69 target price in Monday, August 24 report. Wedbush initiated TESARO Inc (NASDAQ:TSRO) rating on Thursday, January 21. Wedbush has “Outperform” rating and $72 price target. The rating was maintained by FBR Capital with “Outperform” on Monday, October 10. The rating was maintained by Wedbush with “Outperform” on Monday, October 10. Wells Fargo initiated TESARO Inc (NASDAQ:TSRO) on Friday, December 4 with “Outperform” rating. Lake Street initiated the stock with “Buy” rating in Friday, February 5 report. As per Monday, October 10, the company rating was upgraded by Bank of America. Citigroup initiated the stock with “Buy” rating in Thursday, March 17 report.
According to Zacks Investment Research, “Tesaro, Inc. is an oncology-focused biopharmaceutical company for cancer patients. The Company’s product portfolio consists of Rolapitant, a neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting, TSR-011, an orally available anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer and other cancer indications, and Niraparib, an orally active and potent poly (ADP-ribose) polymerase inhibitor for the treatment of patients with solid tumors. Tesaro, Inc. is based in Waltham, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.55 in 2016 Q2. Its up 0.32, from 1.23 in 2016Q1. The ratio is positive, as 24 funds sold all TESARO Inc shares owned while 36 reduced positions. 34 funds bought stakes while 59 increased positions. They now own 44.90 million shares or 3.32% less from 46.44 million shares in 2016Q1.
Mutual Of America Capital Management Limited Liability Company reported 39,320 shares or 0.07% of all its holdings. Fmr holds 0.07% of its portfolio in TESARO Inc (NASDAQ:TSRO) for 6.10M shares. Venbio Select Advisor Ltd Co owns 514,000 shares or 9.6% of their US portfolio. Great West Life Assurance Can holds 0% or 3,500 shares in its portfolio. Blackrock Inv Ltd Liability has 0.01% invested in the company for 115,081 shares. Blackrock holds 0% or 4,968 shares in its portfolio. Teacher Retirement System Of Texas has invested 0% of its portfolio in TESARO Inc (NASDAQ:TSRO). Smith Asset Management Grp L P holds 4,830 shares or 0.01% of its portfolio. The Massachusetts-based Cormorant Asset Management Ltd has invested 4.33% in TESARO Inc (NASDAQ:TSRO). Moreover, Columbus Circle has 0.08% invested in TESARO Inc (NASDAQ:TSRO) for 96,855 shares. Two Sigma Secs Ltd Liability Com holds 0.31% or 6,855 shares in its portfolio. California Pub Employees Retirement System holds 0.01% of its portfolio in TESARO Inc (NASDAQ:TSRO) for 56,200 shares. The Massachusetts-based Pioneer Investment Mngmt has invested 0.04% in TESARO Inc (NASDAQ:TSRO). Tiaa Cref Invest Management owns 85,908 shares or 0.01% of their US portfolio. Jpmorgan Chase holds 0% of its portfolio in TESARO Inc (NASDAQ:TSRO) for 270 shares.
Insider Transactions: Since June 10, 2016, the stock had 0 insider buys, and 5 insider sales for $4.39 million net activity. $929,321 worth of TESARO Inc (NASDAQ:TSRO) was sold by Hanke Jeffrey H.. English Edward C sold $619,803 worth of stock. $44,113 worth of TESARO Inc (NASDAQ:TSRO) was sold by Huber Martin H. Jr..
TESARO, Inc. is an oncology-focused biopharmaceutical company. The company has a market cap of $5.83 billion. The Firm acquires, in-licenses and develops oncology product candidates. It currently has negative earnings. It operates in business of developing and commercializing oncology-focused therapeutics segment.
TSRO Company Profile
TESARO, Inc. (TESARO), incorporated on March 26, 2010, is an oncology-focused biopharmaceutical company. The Firm acquires, in-licenses and develops oncology product candidates. The Firm operates in business of developing and commercializing oncology-focused therapeutics segment. The Firm has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
More news for TESARO Inc (NASDAQ:TSRO) were recently published by: Fool.com, which released: “Why Tesaro, Inc. Is Skyrocketing 20% Today” on October 10, 2016. Investorplace.com‘s article titled: “Why Alphabet Inc (GOOG), Mylan NV (MYL) And Tesaro Inc (TSRO) Are 3 of Today’s …” and published on October 10, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.